Magnum Experiment 23A
HMV
Asset Allocation
Position | Category/Sector | Target Weight |
---|---|---|
ADMA Biologics, Inc. | Healthcare | 23.44% |
AppLovin Corporation | Technology | 21.45% |
Arcutis Biotherapeutics, Inc. | Healthcare | 11.07% |
Carvana Co. | Consumer Cyclical | 15.29% |
Innodata Inc. | Technology | 5.91% |
Longboard Pharmaceuticals, Inc. | Healthcare | 1.47% |
MicroStrategy Incorporated | Technology | 8.51% |
Summit Therapeutics Inc. | Healthcare | 1.77% |
Nuscale Power Corp | Industrials | 4.71% |
TeraWulf Inc. | Financial Services | 6.39% |
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Magnum Experiment 23A, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced every 3 months.
The earliest data available for this chart is Mar 1, 2022, corresponding to the inception date of SMR
Returns By Period
YTD | 1M | 6M | 1Y | 5Y* | 10Y* | |
---|---|---|---|---|---|---|
S&P 500 | 0.62% | -1.93% | 5.98% | 23.72% | 12.67% | 11.33% |
Magnum Experiment 23A | 5.28% | -3.59% | 88.97% | 353.82% | N/A | N/A |
Portfolio components: | ||||||
ADMA Biologics, Inc. | 8.22% | -3.38% | 50.77% | 274.19% | 32.82% | 5.81% |
AppLovin Corporation | 1.66% | 2.54% | 301.41% | 712.24% | N/A | N/A |
Arcutis Biotherapeutics, Inc. | 9.62% | 16.12% | 42.31% | 268.84% | N/A | N/A |
Carvana Co. | -3.13% | -16.71% | 51.62% | 321.48% | 17.65% | N/A |
Innodata Inc. | -6.98% | -3.97% | 121.98% | 388.18% | 100.40% | 29.73% |
Longboard Pharmaceuticals, Inc. | 0.00% | 0.00% | 56.36% | 164.70% | N/A | N/A |
MicroStrategy Incorporated | 14.53% | -12.09% | 144.16% | 486.38% | 88.07% | 35.62% |
Summit Therapeutics Inc. | 5.46% | 4.73% | 116.82% | 525.25% | 67.48% | N/A |
Nuscale Power Corp | 9.76% | -11.11% | 50.69% | 677.87% | N/A | N/A |
TeraWulf Inc. | -2.65% | -18.01% | 16.00% | 159.91% | 2.92% | -8.58% |
Monthly Returns
The table below presents the monthly returns of Magnum Experiment 23A, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 13.59% | 17.16% | 22.96% | -8.09% | 40.19% | 13.36% | 9.86% | 24.54% | 17.50% | -0.78% | 40.33% | -13.02% | 365.45% |
2023 | 4.46% | -0.15% | -4.54% | 2.75% | 14.49% | 0.06% | 16.19% | -3.78% | -13.39% | -8.32% | 5.68% | 23.63% | 35.93% |
2022 | 0.31% | -17.47% | -3.09% | -10.31% | 14.95% | 2.79% | -16.16% | 5.74% | 5.43% | 5.26% | -16.35% |
Expense Ratio
Magnum Experiment 23A has an expense ratio of 0.00%, indicating no management fees are charged. Below you can find the expense ratios of portfolio funds side-by-side and effortlessly compare their relative costs.
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 99, Magnum Experiment 23A is among the top 1% of portfolios on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Martin ratio | |
---|---|---|---|---|---|
ADMA Biologics, Inc. | 4.39 | 4.94 | 1.66 | 11.61 | 30.96 |
AppLovin Corporation | 9.36 | 7.10 | 1.94 | 21.00 | 98.34 |
Arcutis Biotherapeutics, Inc. | 3.35 | 3.61 | 1.42 | 3.15 | 12.93 |
Carvana Co. | 3.91 | 4.41 | 1.53 | 4.25 | 32.76 |
Innodata Inc. | 2.87 | 3.69 | 1.50 | 6.08 | 14.77 |
Longboard Pharmaceuticals, Inc. | 1.65 | 2.81 | 1.37 | 4.04 | 8.43 |
MicroStrategy Incorporated | 4.09 | 3.62 | 1.42 | 9.79 | 21.08 |
Summit Therapeutics Inc. | 1.79 | 5.24 | 1.69 | 9.56 | 20.08 |
Nuscale Power Corp | 4.95 | 3.82 | 1.46 | 7.58 | 22.57 |
TeraWulf Inc. | 1.39 | 2.39 | 1.25 | 1.90 | 7.26 |
Dividends
Dividend yield
Magnum Experiment 23A provided a 0.00% dividend yield over the last twelve months.
TTM | 2024 | 2023 | 2022 | 2021 | |
---|---|---|---|---|---|
Portfolio | 0.00% | 0.00% | 0.00% | 0.00% | 2.12% |
Portfolio components: | |||||
ADMA Biologics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
AppLovin Corporation | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Arcutis Biotherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Carvana Co. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Innodata Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Longboard Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MicroStrategy Incorporated | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Summit Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Nuscale Power Corp | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TeraWulf Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 33.22% |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Magnum Experiment 23A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Magnum Experiment 23A was 41.36%, occurring on May 11, 2022. Recovery took 297 trading sessions.
The current Magnum Experiment 23A drawdown is 12.46%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-41.36% | Apr 5, 2022 | 26 | May 11, 2022 | 297 | Jul 19, 2023 | 323 |
-32.77% | Aug 15, 2023 | 49 | Oct 23, 2023 | 52 | Jan 8, 2024 | 101 |
-19% | Jul 17, 2024 | 16 | Aug 7, 2024 | 2 | Aug 9, 2024 | 18 |
-16.85% | Nov 21, 2024 | 27 | Dec 31, 2024 | — | — | — |
-14.64% | Mar 2, 2022 | 4 | Mar 7, 2022 | 15 | Mar 28, 2022 | 19 |
Volatility
Volatility Chart
The current Magnum Experiment 23A volatility is 15.81%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Diversification
Asset Correlations Table
LBPH | SMMT | SMR | ARQT | ADMA | INOD | WULF | APP | CVNA | MSTR | |
---|---|---|---|---|---|---|---|---|---|---|
LBPH | 1.00 | 0.11 | 0.10 | 0.11 | 0.14 | 0.15 | 0.12 | 0.17 | 0.14 | 0.16 |
SMMT | 0.11 | 1.00 | 0.09 | 0.23 | 0.20 | 0.19 | 0.15 | 0.17 | 0.17 | 0.16 |
SMR | 0.10 | 0.09 | 1.00 | 0.23 | 0.23 | 0.22 | 0.26 | 0.21 | 0.22 | 0.25 |
ARQT | 0.11 | 0.23 | 0.23 | 1.00 | 0.27 | 0.21 | 0.27 | 0.19 | 0.23 | 0.22 |
ADMA | 0.14 | 0.20 | 0.23 | 0.27 | 1.00 | 0.29 | 0.25 | 0.32 | 0.30 | 0.31 |
INOD | 0.15 | 0.19 | 0.22 | 0.21 | 0.29 | 1.00 | 0.32 | 0.32 | 0.31 | 0.31 |
WULF | 0.12 | 0.15 | 0.26 | 0.27 | 0.25 | 0.32 | 1.00 | 0.34 | 0.37 | 0.50 |
APP | 0.17 | 0.17 | 0.21 | 0.19 | 0.32 | 0.32 | 0.34 | 1.00 | 0.52 | 0.47 |
CVNA | 0.14 | 0.17 | 0.22 | 0.23 | 0.30 | 0.31 | 0.37 | 0.52 | 1.00 | 0.45 |
MSTR | 0.16 | 0.16 | 0.25 | 0.22 | 0.31 | 0.31 | 0.50 | 0.47 | 0.45 | 1.00 |